| Literature DB >> 25197429 |
Lenka Borska1, Ctirad Andrys2, Jan Krejsek2, Vladimir Palicka3, Marcela Chmelarova3, Kvetoslava Hamakova4, Jan Kremlacek1, Zdenek Fiala5.
Abstract
The paper presents a prospective cohort study. Observed group was formed of children with plaque psoriasis (n=19) treated by Goeckerman therapy (GT). The study describes adverse (side) effects associated with application of GT (combined exposure of 3% crude coal tar ointment and UV radiation). After GT we found significantly increased markers of oxidative stress (8-hydroxy-2'-deoxyguanosine, 8-hydroxyguanosine, and 8-hydroxyguanine), significantly increased levels of benzo[a]pyrene-7,8-diol-9,10-epoxide (BPDE) DNA adducts (BPDE-DNA), and significantly increased levels of total number of chromosomal aberrations in peripheral lymphocytes. We found significant relationship between (1) time of UV exposure and total number of aberrated cells and (2) daily topical application of 3% crude coal tar ointment (% of body surface) and level of BPDE-DNA adducts. The findings indicated increased hazard of oxidative stress and genotoxic effects related to the treatment. However, it must be noted that the oxidized guanine species and BPDE-DNA adducts also reflect individual variations in metabolic enzyme activity (different extent of bioactivation of benzo[a]pyrene to BPDE) and overall efficiency of DNA/RNA repair system. The study confirmed good effectiveness of the GT (significantly decreased PASI score).Entities:
Mesh:
Substances:
Year: 2014 PMID: 25197429 PMCID: PMC4146480 DOI: 10.1155/2014/302528
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Detailed characteristic of the treatment.
| Number of patients | Total duration of GT (days) | Time of UVR exposure (days) | Daily topical application of CCT ointment (% of body surface) |
|---|---|---|---|
| 1 | 22 | 18 | 32 |
| 2 | 17 | 10 | 19 |
| 3 | 18 | 13 | 37 |
| 4 | 22 | 22 | 38 |
| 5 | 22 | 19 | 31 |
| 6 | 18 | 15 | 20 |
| 7 | 14 | 9 | 40 |
| 8 | 14 | 10 | 28 |
| 9 | 17 | 17 | 31 |
| 10 | 14 | 13 | 40 |
| 11 | 19 | 15 | 28 |
| 12 | 21 | 21 | 37 |
| 13 | 22 | 22 | 37 |
| 14 | 14 | 9 | 30 |
| 15 | 14 | 10 | 17 |
| 16 | 17 | 17 | 38 |
| 17 | 22 | 23 | 28 |
| 18 | 17 | 17 | 36 |
| 19 | 18 | 18 | 28 |
The content of selected PAHs in pharmaceutical grade crude coal tar (CCT).
| PAHs | IARCa | mg/g | PAHs | IARCa | mg/g |
|---|---|---|---|---|---|
| Benzo(a)pyrene | 1 | 0.008 | Acenaphthene | 3 | 0.104 |
| Dibenz(a,h)anthracene | 2A | 0 | Anthracene | 3 | 2.494 |
| Benz(a)anthracene | 2B | 0 | Benzo(g,h,i)perylene | 3 | 0 |
| Benzo(b)fluoranthene | 2B | 0 | Fluoranthene | 3 | 0.413 |
| Benzo(k)fluoranthene | 2B | 0 | Fluorene | 3 | 0.299 |
| Chrysene | 2B | 0.028 | Phenanthrene | 3 | 2.520 |
| Indeno(1,2,3-c,d)pyrene | 2B | 0 | Pyrene | 3 | 0.241 |
| Naphthalene | 2B | 3.286 | Acenaphthylene | — | 0.153 |
aClassification according to WHO (IARC Monographs on the Evaluation of Carcinogenic Risk to Humans, Volumes 1–109, 2014):
Group 1: the agent is carcinogenic to humans;
Group 2A: the agent is probably carcinogenic to humans;
Group 2B: the agent is possibly carcinogenic to humans;
Group 3: the agent is not classifiable as to its carcinogenicity to humans.
Oxidative damage of DNA/RNA, BPDE-DNA adducts, and chromosomal aberrations in children treated by GT.
| Oxidative damage of DNA and RNAa | Significance of differences | |
|---|---|---|
| Before GT | After GT | |
| ( | ( | |
| 2557 | 2687 |
|
| (2008–2789) | (2146–3238) | |
|
| ||
| BPDE-DNA adductsb | Significance of differences | |
| Before GT | After GT | |
| ( | ( | |
|
| ||
| 5.65 | 7.2 |
|
| (4.97–7.3) | (5.35–7.9) | |
|
| ||
| Chromosomal aberration in peripheral lymphocytesc | Significance of differences | |
| Before GT | After GT | |
| ( | ( | |
|
| ||
| Structurally aberrated cells | ||
| 0.0 | 1.0 |
|
| (0.0-0.0) | (0.0–1.0) | |
|
| ||
| Numerically aberrated cells | ||
| 0.0 | 0.0 | NS |
| (0.0-0.0) | (0.0–1.0) | |
|
| ||
| Total number of aberrated cells | ||
| 0.0 | 1.0 |
|
| (0.0-0.0) | (0.0–1.0) | |
aOxidative damage of DNA and RNA is presented as the sum of three oxidized guanine species in serum: 8-hydroxy-2′-deoxyguanosine from DNA, 8-hydroxyguanosine from RNA, and 8-hydroxyguanine from either DNA or RNA. The levels are expressed as pg of the sum of oxidized guanine species per mL of serum. The average concentration is presented as median and lower-upper quartile because of nonnormal data distribution; P: Wilcoxon matched-pairs test.
bThe levels are expressed as ng of BPDE-DNA adducts per µg of DNA and the average concentration is presented as median and lower-upper quartile because of nonnormal data distribution; P: Wilcoxon matched-pairs test.
cThe levels are expressed as percentage of structurally aberrated cells (SAC), numerically aberrated cells (NAC), and total number of aberrated cells (ABC). The average levels of aberration are presented as median and lower-upper quartile because of nonnormal data distribution; P: Wilcoxon matched-pairs test; NS: nonsignificant difference.
Figure 1Distribution of values of oxidative damage of DNA and RNA. The oxidative damage of DNA/RNA is presented as the sum of three oxidized guanine species per mL of serum. Scatter plot depicts anti-BPDE-DNA values before and after the GT therapy. All together 19 dots represent 38 measurements; each dot belongs to a one patient. The top histogram shows data distribution before treatment; the right side histogram corresponds to the posttreatment values distribution. The white zones represent nonsmokers data, and the black zones depict smokers' ones. NA: statistically not available.
Figure 2Distribution of values of BPDE-DNA adducts. The levels are expressed as ng of BPDE-DNA adducts per μg of DNA. Scatter plot depicts BPDE-DNA values before and after the GT therapy. All together 14 dots represent 28 measurements; each dot belongs to a one patient. The top histogram shows data distribution before treatment; the right side histogram corresponds to the posttreatment values distribution. The white zones represent nonsmokers data, and the black zones depict smokers' ones. NA: statistically not available.
Figure 3Distribution of values of chromosomal aberration in peripheral lymphocytes (total number of aberrated cells). The levels are expressed as percentage of total number of aberrated cells (ABC). Scatter plot depicts ABC values before and after the GT therapy. All together 5 dots represent 19 subjects and 38 measurements; number of patients belonging to one dot is shown in histograms. The top histogram shows data distribution before treatment; the right side histogram corresponds to the posttreatment values distribution. The white zones represent nonsmokers data, and the black zones depict smokers' ones. NA: statistically not available.
Figure 4Distribution of PASI score. The levels are dimensionless. Scatter plot depicts PASI score before and after the GT therapy. All together 18 dots represent 38 measurements; each dot belongs at least to a one patient. The top histogram shows data distribution before treatment; the right side histogram corresponds to the posttreatment values distribution. The white zones represent nonsmokers data, and the black zones depict smokers' ones. NA: statistically not available.
The associations between monitored biomarkers (levels after GT) and important characteristics of exposure (Spearman Rank Order Correlations).
| Total duration | Time of UVR exposure | Daily topical application of CCT ointment (% of body surface) | |
|---|---|---|---|
| Oxidative damage of DNA and RNAa | NS | NS | NS |
| BPDE-DNA adductsb | NS | NS |
|
| Total number of aberrated cellsc | NS |
| NS |
| PASI scored | NS | NS |
|
aUnit: pg of the sum of three oxidized guanine species per ml of serum.
bUnit: ng of BPDE-DNA adducts per µg of DNA.
cUnit: percentage of total number of aberrated cells (ABC).
dDimensionless.